XIGDUO XR Drug Patent Profile

Which patents cover Xigduo Xr, and when can generic versions of Xigduo Xr launch?

Xigduo Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in XIGDUO XR is dapagliflozin; metformin hydrochloride. There are twenty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xigduo Xr

A generic version of XIGDUO XR was approved as dapagliflozin; metformin hydrochloride by ALKEM LABS LTD on April 6^th, 2026.

Summary for XIGDUO XR

International Patents:	236
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
Drug Prices:	Drug price information for XIGDUO XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XIGDUO XR
DailyMed Link:	XIGDUO XR at DailyMed

See drug prices for XIGDUO XR

Recent Clinical Trials for XIGDUO XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chinese University of Hong Kong	PHASE4
AstraZeneca	PHASE4
Beni-Suef University	Phase 3

See all XIGDUO XR clinical trials

Pharmacology for XIGDUO XR

Drug Class	Biguanide Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for XIGDUO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIGDUO XR	Extended-release Tablets	dapagliflozin; metformin hydrochloride	2.5 mg/1000 mg	205649	1	2018-10-29
XIGDUO XR	Extended-release Tablets	dapagliflozin; metformin hydrochloride	5 mg/500 mg 5 mg/1000 mg 10 mg/500 mg 10 mg/1000 mg	205649	10	2018-01-08

US Patents and Regulatory Information for XIGDUO XR

XIGDUO XR is protected by five US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014	AB	RX	Yes	No					Y
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-004	Oct 29, 2014	AB	RX	Yes	Yes
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014	AB	RX	Yes	No					Y

Expired US Patents for XIGDUO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-002	Oct 29, 2014
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-001	Oct 29, 2014

International Patents for XIGDUO XR

When does loss-of-exclusivity occur for XIGDUO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Norway

Poland

Portugal

Russian Federation

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XIGDUO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	026024	COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS
Argentina	040032	C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO
Austria	295848

Supplementary Protection Certificates for XIGDUO XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	C300585	Netherlands		PRODUCT NAME: DAPAGLIFLOZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	PA2013008	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211	122013000033	Germany		PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112

XIGDUO XR (dapagliflozin/metformin HCl extended-release): market dynamics and financial trajectory

Last updated: July 24, 2026

Xigduo XR (dapagliflozin/metformin HCl extended-release) is an oral, fixed-dose combination branded medicine positioned in type 2 diabetes for glycemic control. Revenue trajectory is driven by (1) SGLT2 class growth and class competition, (2) mix shift within diabetes portfolios toward once-daily and combination products, and (3) payer restrictions tied to SGLT2 formulary placement and metformin IR/ER conversion dynamics. Financial performance is also exposed to brand erosion from the underlying metformin component and to long-term SGLT2 competitive pressure as additional agents and fixed-dose combinations gain share.

How is XIGDUO XR positioned in the type 2 diabetes market and what share drivers matter?

Core positioning. Xigduo XR combines an SGLT2 inhibitor (dapagliflozin) with metformin ER in a single extended-release product. Commercially it competes in the “oral combination” segment where prescribers seek early add-on therapy and simplified regimens.

Key market structure factors affecting uptake

• Class tailwinds for SGLT2 inhibitors. Dapagliflozin is part of the SGLT2 class, which has benefited from broad evidence adoption for cardiovascular and renal outcomes in type 2 diabetes and wider label support in subsets of patients.
• Payer controls. Managed care typically uses step edits and formulary tiering that can constrain diffusion unless the combination is the plan’s preferred branded option.
• Switching behavior to fixed-dose combinations. Fixed-dose regimens often outperform separate-titration initiation due to adherence and reduced pill burden. However, conversion depends on plan coverage for the combination versus covering dapagliflozin and metformin as separate generics.

What patient profiles most influence XIGDUO XR demand?

High-propensity patients

• Patients already on metformin ER who need an SGLT2 add-on.
• Patients inadequately controlled on monotherapy or early combination therapy, where clinicians prefer once-daily combination regimens.
• Patients where clinicians seek both glycemic control and cardiorenal risk reduction consistent with SGLT2 evidence uptake.

Low-propensity segments

• Patients newly started on metformin IR with plan designs that restrict ER switching.
• Patients in formularies that preferentially list other SGLT2 fixed-dose combinations or direct generic metformin escalation strategies.

What are the main competitive dynamics vs other dapagliflozin/metformin and SGLT2 combinations?

Xigduo XR competes on three fronts:

1. Other fixed-dose dapagliflozin/metformin products (where applicable in the market).
2. Other SGLT2-based fixed-dose combinations (dapagliflozin paired with other complements, and competing SGLT2 agents paired with metformin or other agents).
3. SGLT2 monotherapy plus generic metformin strategies that can win coverage and price comparisons.

Which competitive factors affect prescription switching?

• Formulary placement and prior authorization. SGLT2s commonly require documentation of inadequate glycemic control or prior therapy.
• Net price and rebate intensity. Fixed-dose brands often face intense rebate negotiations against other SGLT2 combinations and against “generic metformin + branded SGLT2” fallbacks.
• Dosing convenience. Once-daily regimens and ER formulations can win adherence-based utilization, but only when coverage supports them.

How does XIGDUO XR compare with separate therapy (generic metformin + branded SGLT2)?

Separate therapy can be cost-efficient for payers because metformin is largely generic. That reduces the economic advantage of a fixed-dose brand unless:

• rebates materially narrow price gaps, or
• the combination is used to improve adherence and reduce clinical management friction for the payer network.

When does XIGDUO XR face exclusivity and generic entry risk, and how could it affect revenue?

Brand financial trajectory for Xigduo XR is shaped by the durability of exclusivity around:

• fixed-dose product formulation and composition-of-matter coverage (if present),
• method-of-use coverage (if present), and
• data exclusivity and regulatory exclusivity tied to the original NDA approval package.

Generic entry risk can emerge when:

• Orange Book-listed patents are cleared for generic challenge pathways, or
• settlement agreements permit early launch timelines for authorized or at-risk generics.

Revenue impact path (commercial).

• Pre-launch: net price erosion through rebate pressure as plans seek to anticipate substitutes.
• Launch: abrupt share transfer if the generic is substitutable and placed on formulary at lower tiers.
• Post-launch: long tail shrink as prescribers remain on therapy for patients already stabilized, but incident prescriptions switch.

What is the Orange Book status and patent landscape that drives launch timing?

The Orange Book listing structure determines whether challengers can use Paragraph IV mechanisms and the extent of automatic stays. The financial trajectory therefore depends on:

• whether product-specific patents remain enforceable,
• whether litigation results in stays, partial settlements, or launch approvals, and
• whether settlements include branded-withdrawal or “authorized generic” arrangements.

What has XIGDUO XR’s financial trajectory looked like (revenue, growth, and earnings sensitivity)?

A credible financial trajectory analysis requires audited or filing-based revenue data (company reported net sales, segment reporting, and payer utilization), plus timeline mapping to FDA/regulatory events and patent milestones. Without those numeric inputs, no complete and accurate financial trajectory can be produced.

How do FDA pathway milestones and labeling changes affect XIGDUO XR adoption?

Adoption is influenced by:

• initial labeling scope and subsequent label expansions,
• safety communications that alter prescribing comfort,
• renal function criteria and dose limitations, which affect suitability and continuity of use.

For SGLT2-based products, label and risk communications (including renal outcomes considerations and glycemic event monitoring) can shift prescriber behavior and payer coverage.

What labeling elements typically change utilization in SGLT2/metformin combinations?

• Indications for glycemic control in relevant patient subsets.
• Renal function thresholds that affect who can start and who can continue.
• Contraindication or monitoring guidance that impacts formulary and PA criteria.

What commercial metrics best explain XIGDUO XR demand trends?

The most decision-relevant indicators for Xigduo XR dynamics are:

• TRx and new-to-brand scripts
• persistency and switching
• share of prescriptions within oral combination diabetes
• formulary penetration and tier placement
• estimated net price and rebate rate versus key comparators

Financial performance is typically a function of both unit and price:

• unit volume is sensitive to competitor coverage and step therapy design,
• net price is sensitive to rebate negotiations as formulary competition intensifies.

How do payer contracting and pharmacy benefit design influence XIGDUO XR net sales?

SGLT2 combinations often face:

• rebate-driven preferred positioning for top formulary tiers,
• step edits that delay utilization until baseline metformin therapy criteria are satisfied,
• quantity limits or product selection rules within ER versus IR metformin lines.

Fixed-dose combinations can still be “preferred” when:

• rebates match or beat the cost of separate components on the plan’s net basis, and
• adherence metrics or clinical pathways reduce total medical costs for the plan.

What generic launch scenarios are most relevant for XIGDUO XR and what are the revenue risks?

Generic launch scenarios generally fall into three categories:

1. Delayed entry due to enforceable patents and litigation stays.
2. At-risk or authorized generic entry near expiration, with rapid market share erosion.
3. Partial erosion when branded uptake continues due to prescriber inertia and patient stability, but incident scripts shift.

Revenue risk factors

• Magnitude of formulary disruption at generic entry.
• Availability of alternative combinations that maintain branded usage.
• Payer switching algorithms that force therapy changes at renewal.

Key takeaways

• Xigduo XR’s market dynamics are dominated by SGLT2 class growth, fixed-dose combination adoption, and payer formulary controls.
• Competitive pressure comes from SGLT2 fixed-dose alternatives and from separate therapy strategies using generic metformin plus branded SGLT2s.
• The revenue trajectory depends on the timing and outcome of patent and exclusivity events that determine generic entry pathways and whether launch occurs quickly or remains delayed by litigation stays.
• Financial outcomes should be evaluated through TRx/new-to-brand trends, formulary tiering and net price/rebate pressure, and launch sensitivity tied to generic substitution timing.

FAQs

1) What is XIGDUO XR used for in type 2 diabetes?
Xigduo XR is used as an oral treatment for glycemic control in adults with type 2 diabetes, combining dapagliflozin with metformin extended-release.

2) Does XIGDUO XR have cardiovascular or renal outcome implications like other SGLT2 inhibitors?
Its adoption is shaped by SGLT2 class evidence and label structure that supports cardiorenal risk reduction in relevant patient populations.

3) What usually drives formulary placement decisions for SGLT2/metformin fixed-dose combinations?
Net price after rebates, evidence-based positioning, prior authorization feasibility, and step-therapy alignment with plan utilization patterns.

4) How quickly do SGLT2 combination brands lose share after generic entry?
Share erosion timing depends on substitution policy, tier placement, and whether alternate preferred combinations remain branded; incident prescriptions typically shift faster than stable patients discontinue.

5) What risks matter most for long-term XIGDUO XR revenue durability?
Patent-enforced delay versus generic launch timing, intensity of competition from other SGLT2 combinations, and payer contracting that increasingly favors lowest-net-cost options.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Packages and Labeling for Xigduo XR (dapagliflozin and metformin HCl extended-release). U.S. Food and Drug Administration.
3. FDA. Drug Safety Communications related to SGLT2 inhibitors. U.S. Food and Drug Administration.